KERRY POWELL: Open Payments
NPI 1477092211 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$956 in 33 payments from 13 companies in 2025. Trend: 2023 $684 · 2024 $1,111 · 2025 $956
Food & beverage: $956
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 5 | $242 |
| Novartis Pharmaceuticals Corporation | 8 | $219 |
| ABBVIE INC. | 7 | $154 |
| Lundbeck LLC | 2 | $64 |
| Janssen Biotech, Inc. | 2 | $55 |
| Genentech USA, Inc. | 2 | $50 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| SK Life Science, Inc. | 1 | $31 |
| Averitas Pharma Inc. | 1 | $24 |
| Abbott Laboratories | 1 | $24 |
Products named: KESIMPTA, VYVGART, VYVGART HYTRULO, QULIPTA, VYEPTI, Ocrevus Zunovo, UBRELVY, INGREZZA.
Industry payments across FL — which companies pay providers there.
